Bulltick Wealth Management LLC Invests $159,000 in Takeda Pharmaceutical Co. $TAK

Bulltick Wealth Management LLC acquired a new position in Takeda Pharmaceutical Co. (NYSE:TAK) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,254 shares of the company’s stock, valued at approximately $159,000.

Other institutional investors also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. bought a new stake in Takeda Pharmaceutical during the first quarter valued at about $51,049,000. Goldman Sachs Group Inc. lifted its position in shares of Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after buying an additional 692,404 shares in the last quarter. ABC Arbitrage SA bought a new position in shares of Takeda Pharmaceutical during the 1st quarter valued at approximately $4,994,000. Graham Capital Management L.P. purchased a new stake in Takeda Pharmaceutical in the 1st quarter worth approximately $2,361,000. Finally, Carrera Capital Advisors bought a new stake in Takeda Pharmaceutical during the 2nd quarter worth approximately $2,153,000. 9.17% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on TAK. Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Tuesday, November 11th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $14.30 on Monday. The firm has a market cap of $45.49 billion, a price-to-earnings ratio of 47.65 and a beta of 0.16. The firm has a fifty day moving average price of $14.34 and a 200 day moving average price of $14.64. Takeda Pharmaceutical Co. has a fifty-two week low of $12.80 and a fifty-two week high of $15.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.44 EPS for the quarter, hitting the consensus estimate of $0.44. The business had revenue of $7.32 billion for the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.